Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies

  • Vinicius Lins Ferreira
  • Letícia Paula Leonart
  • Fernanda Stumpf Tonin
  • Helena Hiemisch Lobo Borba
  • Roberto Pontarolo
Systematic Review

Abstract

Background and Objectives

Hepatitis C treatment has changed considerably in recent years, and many interferon (IFN)-free therapies are now available. Considering the high rates of sustained virological response (SVR) presented by clinical trials for these treatments, high rates of effectiveness are also expected in real-world clinical practice. Hence, this study aimed to conduct a systematic review and meta-analysis of observational cohort studies to evaluate the clinical effectiveness and safety of IFN-free therapies for hepatitis C.

Methods

The search was performed in four electronic databases and included cohort studies that evaluated IFN-free schemes and provided data on SVR at 12 weeks after the end of treatment (SVR12) as the primary outcome. Overall and subgroup meta-analyses of patients’ clinical conditions (e.g. co-infection with human immunodeficiency virus (HIV), cirrhosis, liver transplant, specific genotypes, and other conditions) were performed.

Results

Sixty-eight studies encompassing a total of 24,151 patients were included for quantitative and qualitative analyses, evaluating six treatments: sofosbuvir with ledipasvir, daclatasvir, or simeprevir; daclatasvir with asunaprevir; paritaprevir/ritonavir in combination with ombitasvir and dasabuvir; and sofosbuvir with ribavirin. The overall analysis showed SVR rates of 88–96% for all treatments except sofosbuvir combined with ribavirin, which had SVR rates of approximately 80%. The results of subgroup analyses showed that the genotype 3 virus appears to be the most difficult to treat.

Conclusion

In order to choose the best treatment option, it is necessary to consider the patients’ conditions and characteristics. In conclusion, the use of IFN-free therapies meets the high expectations created by clinical trials, including patients in special clinical conditions.

Notes

Compliance with Ethical Standards

Funding

None.

Conflict of interest

Vinicius Lins Ferreira, Letícia Paula Leonart, Fernanda Stumpf Tonin, Helena Hiemisch Lobo Borba, and Roberto Pontarolo declare no relevant conflicts of interest.

Supplementary material

40261_2018_624_MOESM1_ESM.pdf (988 kb)
Supplementary material 1 (PDF 987 kb)

References

  1. 1.
    World Health Organization (WHO). Hepatitis C fact sheet no. 164 (updated July 2017). http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 10 Aug 2017.
  2. 2.
    EASL. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245–64.CrossRefGoogle Scholar
  3. 3.
    Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8:212–23.CrossRefPubMedGoogle Scholar
  4. 4.
    EASL. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.CrossRefGoogle Scholar
  5. 5.
    American Association for the Study of Liver Diseases. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–54.CrossRefGoogle Scholar
  6. 6.
    Ahmed H, Abushouk AI, Menshawy A, Mohamed A, Negida A, Loutfy SA, et al. Safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin for treatment of hepatitis C virus genotype 1: a systematic review and meta-analysis. Clin Drug Investig. 2017;37:1009–23.CrossRefPubMedGoogle Scholar
  7. 7.
    World Health Organization. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection. Updated version, 2016. Geneva: World Health Organization; 2016.Google Scholar
  8. 8.
    Ferreira VL, Tonin FS, Assis Jarek NA, Ramires Y, Pontarolo R. Efficacy of Interferon-free therapies for chronic hepatitis C: a systematic review of all randomized clinical trials. Clin Drug Investig. 2017;37(7):635–46.CrossRefPubMedGoogle Scholar
  9. 9.
    Ferreira VL, Assis Jarek NA, Tonin FS, Borba HH, Wiens A, Muzzillo DA, et al. Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis. J Gastroenterol Hepatol. 2017;32(4):749–55.CrossRefPubMedGoogle Scholar
  10. 10.
    Ferreira VL, Assis Jarek NA, Tonin FS, Borba HH, Wiens A, Pontarolo R. Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. J Clin Pharm Ther. 2016;41(5):478–85.CrossRefPubMedGoogle Scholar
  11. 11.
    Mariani AW, Pego-Fernandes PM. Observational studies: why are they so important? Sao Paulo Med J. 2014;132:01–2.CrossRefGoogle Scholar
  12. 12.
    Ligthelm RJ, Borzì V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational studies in clinical practice. Clin Ther. 2007;29:1284–92.CrossRefGoogle Scholar
  13. 13.
    O’Neil M, Berkman N, Hartling L, Chang S, Anderson J, Motu’apuaka M, et al. Observational evidence and strength of evidence domains: case examples. Syst Rev. 2014;3:35.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Schünemann HJ, Tugwell P, Reeves BC, Akl EA, Santesso N, Spencer FA, et al. Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions. Res Synth Methods. 2013;4:49–62.CrossRefPubMedGoogle Scholar
  15. 15.
    Barnish MS, Turner S. The value of pragmatic and observational studies in health care and public health. Pragmat Obs Res. 2017;8:49–55.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    DiPietro NA. Methods in epidemiology: observational study designs. Pharmacotherapy. 2010;30:973–84.CrossRefPubMedGoogle Scholar
  17. 17.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. Copenhagen: Cochrane Collaboration; 2011.Google Scholar
  19. 19.
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.CrossRefPubMedGoogle Scholar
  20. 20.
    Turner RM, Bird SM, Higgins JP. The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PLoS One. 2013;8:e59202.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2013.Google Scholar
  22. 22.
    Gomaa A, Allam N, Elsharkway A, El Kassas M, Waked I. Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med. 2017;9:17–25.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–28.CrossRefPubMedGoogle Scholar
  24. 24.
    Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599–607.CrossRefPubMedGoogle Scholar
  25. 25.
    Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–17.CrossRefPubMedGoogle Scholar
  26. 26.
    Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Bräu N, Brown A, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377:1448–55.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pharmaceutical Sciences Post-Graduate Program, Department of PharmacyUniversidade Federal do ParanáCuritibaBrazil

Personalised recommendations